Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report.

ABSTRACT: Chromophobe renal cell carcinoma (ChRCC) is a rare pathological type of renal cell carcinoma (RCC). Related systematic studies involving large numbers of patients are lacking, and more importantly, there is currently no international consensus on post-line treatment guidelines for ChRCC. The rapid development of systemic treatment with molecular targeted therapies and immune checkpoint inhibitors has brought effective approaches for patients with clear cell renal cell carcinoma (ccRCC), while progress in the treatment of ChRCC is still limited. In this case report, the patient was initially diagnosed at the early stage; 4 years post-surgery, she developed lung metastases and the disease progressed once again after being treated with sunitinib monotherapy for 3 years. However, after combini

SUBMITTER: Zhang H 

PROVIDER: S-EPMC10869506 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature